No Data
No Data
Even After Rising 20% This Past Week, Fujian Cosunter Pharmaceutical (SZSE:300436) Shareholders Are Still Down 50% Over the Past Three Years
Fujian Cosunter Pharmaceutical (300436.SZ): Plans to complete the construction project of integrated production base for active pharmaceutical ingredients and will permanently supplement working capital with the remaining funds raised.
On July 30th, Gelonhui reported that Fujian Cosunter Pharmaceutical (300436.SZ) held the second meeting of the fifth session of the Board of Directors and the second meeting of the fifth session of the Supervisory Committee on July 30, 2024. They reviewed and passed the Proposal on Part of the Fundraising Projects for Completion and the Permanent Supplementation of Working Capital with the Surplus Raised Funds. The investment project of the active pharmaceutical ingredient and drug preparation integrated production base construction project from the fundraising project for the issuance of A-shares of the company to specific objects on the Growth Enterprise Market in 2020 has reached the intended usable state and meets the completion conditions. The company plans to use the surplus funds of the project to permanently supplement the working capital and authorizes the management of the company at the same time.
Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses
Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
More Unpleasant Surprises Could Be In Store For Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares After Tumbling 28%
Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development
Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now
Guangshengtang (300436.SZ): The total amount involved in the proposed termination of some technical service contracts is RMB 25.613 million
Gelonghui, March 31 | Guangshengtang (300436.SZ) announced that the company and Ruitailai signed a “technical service contract” for 10 drugs in March 2022. In addition to ritonavir tablets, clopidogrel bisulfate, aspirin tablets, and aspirin enteric tablets, this related transaction plans to prematurely terminate the “technical service contracts” for the remaining 7 drugs signed above and sign a “termination agreement”. The total amount involved in the termination of the related transaction agreement was 25.613 million yuan.
No Data